Kodiak Sciences says Zenkuda meets primary endpoint in Phase 3 wet AMD trial
The company said both Zenkuda and tabirafusp-ted matched aflibercept on vision outcomes at one year in the DAYBREAK study.
Story updates
10:36:20 AM UTC
SquawkNews
Sept 28 (Reuters) — Kodiak Sciences Inc.: Zenkuda And Tabirafusp-ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-of-care Profile With Strong Immediacy And Sustained Clinical Effect With Majority Of Patients On 24-week Dosing Interval Using Strict Treat-to-dryness Real World Retreatment Criteria. Kodiak Sciences - Zenkuda Bla Planned For Q4 2026 To Include Five Positive Phase 3 Studies Kodiak Sciences Inc. - Zenkuda And Tabirafusp-ted Demonstrated Safety Consistent With Established Safety Profile Of Aflibercept Source text:... Further company coverage: KOD.O (Reuters.Briefs@thomsonreuters.com;;)